AtriCure, Inc. (ATRC)

NASDAQ: ATRC · IEX Real-Time Price · USD
22.71
-0.49 (-2.11%)
At close: Apr 22, 2024, 4:00 PM
23.00
+0.29 (1.28%)
After-hours: Apr 22, 2024, 7:54 PM EDT
-2.11%
Market Cap 1.10B
Revenue (ttm) 399.25M
Net Income (ttm) -30.44M
Shares Out 48.37M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 662,591
Open 23.21
Previous Close 23.20
Day's Range 22.27 - 23.78
52-Week Range 22.29 - 59.61
Beta 1.37
Analysts Strong Buy
Price Target 51.20 (+125.45%)
Earnings Date May 1, 2024

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensin... [Read more]

Sector Healthcare
IPO Date Aug 5, 2005
Employees 1,050
Stock Exchange NASDAQ
Ticker Symbol ATRC
Full Company Profile

Financial Performance

In 2023, AtriCure's revenue was $399.25 million, an increase of 20.84% compared to the previous year's $330.38 million. Losses were -$30.44 million, -34.49% less than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price forecast is $51.2, which is an increase of 125.45% from the latest price.

Price Target
$51.2
(125.45% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

4 days ago - Business Wire

AtriCure to Announce First Quarter 2024 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

12 days ago - Business Wire

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

27 days ago - Business Wire

AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

2 months ago - Business Wire

AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

3 months ago - Business Wire

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

3 months ago - Business Wire

AtriCure Appoints Shlomi Nachman to the Board of Directors

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

3 months ago - Business Wire

AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...

4 months ago - Business Wire

AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...

5 months ago - Business Wire

AtriCure Releases 2023 ESG Report

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

5 months ago - Business Wire

AtriCure Reports Third Quarter 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

6 months ago - Business Wire

AtriCure to Participate in the Stifel 2023 Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...

6 months ago - Business Wire

AtriCure to Announce Third Quarter 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

6 months ago - Business Wire

AtriCure Reports Second Quarter 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

9 months ago - Business Wire

AtriCure to Participate at Upcoming Investor Conferences

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

9 months ago - Business Wire

AtriCure to Announce Second Quarter 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

10 months ago - Business Wire

AtriCure Reports First Quarter 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

1 year ago - Business Wire

AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

1 year ago - Business Wire

AtriCure to Announce First Quarter 2023 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

1 year ago - Business Wire

AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

1 year ago - Business Wire

AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

1 year ago - Business Wire

AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...

1 year ago - Business Wire

AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-...

1 year ago - Business Wire

AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post...

1 year ago - Business Wire

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-...

1 year ago - Business Wire